Prof. Dr. A.T. van Oosterom (EORTC President 2000-2003)
10 Nov 2021
The international oncology community has lost a true leader. Professor Allan T. van Oosterom studied in The Netherlands and graduated from the University of Leiden. He obtained his PhD in 1976, trained at the US National Cancer Institute and subsequently in 1978 became a Lecturer at the Royal Marsden Hospital in the United Kingdom. He returned to The Netherlands as a Senior Lecturer at the University of Leiden, and then moved to Antwerp in Belgium where he was Head of Oncology for 10 years and subsequently transferred to Leuven. Professor A.T, van Oosterom was always involved in clinical research and more specifically in the field of sarcomas, gynaecological and uro-genital tumours. In that respect, he had long association with the EORTC. He first became a member of the EORTC back in 1974 and took position on the Board of Directors in 1984, and was the EORTC President 2000-2003. In addition, he was a member of many organisations and was notably President of the Federation of European Cancer Societies (FECS). Professor A.T. van Oosterom inspired many doctors and scientists in carrying out forefront cancer clinical research, contributing through his own research agenda and through that of others to major therapeutic improvement for cancer patients.
It is with great sadness that we learn that Professor A.T. van Oosterom passed away. EORTC has lost a major peer who contributed to making oncology what it is today. His vision and dedication, relentlessly chasing the next oncological challenge to solve, collaborating across the world, inspired many oncologists worldwide.
We will remember Professor A.T. van Oosterom as a passionate and talented oncology leader.
Related News
New study confirms a key quality of life tool can be used with adolescents with cancer
9 Jun 2026
“Changing practice, improving lives”: EORTC publishes its Annual Report 2025
8 Jun 2026
This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research
20 May 2026
Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma
1 May 2026
EORTC’s presence at ESTRO 2026
30 Apr 2026
Independent, academic cancer trials are vital to improve patient outcomes worldwide
28 Apr 2026
EORTC Imaging Group Becomes the Diagnostic and Therapeutic Imaging Group
24 Apr 2026
Investing in the future of cancer research; EORTC’s Young and Early Career investigator Network shows its value
23 Apr 2026
In Memoriam of Martine Van Glabbeke (1951-2026)
17 Apr 2026
PEACE-3 trial demonstrates significant overall survival benefit in patients with metastatic castration-resistant prostate cancer with bone metastases
27 Feb 2026
